S&P 500   4,274.93 (+1.28%)
DOW   33,630.01 (+1.72%)
QQQ   355.11 (+0.88%)
AAPL   180.53 (+0.24%)
MSFT   334.89 (+0.69%)
META   273.44 (+0.30%)
GOOGL   125.15 (+1.16%)
AMZN   125.21 (+1.99%)
TSLA   216.71 (+4.43%)
NVDA   398.11 (+0.10%)
NIO   7.69 (+1.99%)
BABA   85.09 (+2.52%)
AMD   120.41 (+0.79%)
T   15.05 (-4.81%)
F   12.48 (+3.06%)
MU   69.50 (+0.59%)
CGC   0.84 (+0.75%)
GE   105.65 (+0.94%)
DIS   90.77 (+2.46%)
AMC   4.58 (+0.66%)
PFE   38.60 (+1.53%)
PYPL   63.97 (+1.46%)
NFLX   404.12 (+0.25%)
S&P 500   4,274.93 (+1.28%)
DOW   33,630.01 (+1.72%)
QQQ   355.11 (+0.88%)
AAPL   180.53 (+0.24%)
MSFT   334.89 (+0.69%)
META   273.44 (+0.30%)
GOOGL   125.15 (+1.16%)
AMZN   125.21 (+1.99%)
TSLA   216.71 (+4.43%)
NVDA   398.11 (+0.10%)
NIO   7.69 (+1.99%)
BABA   85.09 (+2.52%)
AMD   120.41 (+0.79%)
T   15.05 (-4.81%)
F   12.48 (+3.06%)
MU   69.50 (+0.59%)
CGC   0.84 (+0.75%)
GE   105.65 (+0.94%)
DIS   90.77 (+2.46%)
AMC   4.58 (+0.66%)
PFE   38.60 (+1.53%)
PYPL   63.97 (+1.46%)
NFLX   404.12 (+0.25%)
S&P 500   4,274.93 (+1.28%)
DOW   33,630.01 (+1.72%)
QQQ   355.11 (+0.88%)
AAPL   180.53 (+0.24%)
MSFT   334.89 (+0.69%)
META   273.44 (+0.30%)
GOOGL   125.15 (+1.16%)
AMZN   125.21 (+1.99%)
TSLA   216.71 (+4.43%)
NVDA   398.11 (+0.10%)
NIO   7.69 (+1.99%)
BABA   85.09 (+2.52%)
AMD   120.41 (+0.79%)
T   15.05 (-4.81%)
F   12.48 (+3.06%)
MU   69.50 (+0.59%)
CGC   0.84 (+0.75%)
GE   105.65 (+0.94%)
DIS   90.77 (+2.46%)
AMC   4.58 (+0.66%)
PFE   38.60 (+1.53%)
PYPL   63.97 (+1.46%)
NFLX   404.12 (+0.25%)
S&P 500   4,274.93 (+1.28%)
DOW   33,630.01 (+1.72%)
QQQ   355.11 (+0.88%)
AAPL   180.53 (+0.24%)
MSFT   334.89 (+0.69%)
META   273.44 (+0.30%)
GOOGL   125.15 (+1.16%)
AMZN   125.21 (+1.99%)
TSLA   216.71 (+4.43%)
NVDA   398.11 (+0.10%)
NIO   7.69 (+1.99%)
BABA   85.09 (+2.52%)
AMD   120.41 (+0.79%)
T   15.05 (-4.81%)
F   12.48 (+3.06%)
MU   69.50 (+0.59%)
CGC   0.84 (+0.75%)
GE   105.65 (+0.94%)
DIS   90.77 (+2.46%)
AMC   4.58 (+0.66%)
PFE   38.60 (+1.53%)
PYPL   63.97 (+1.46%)
NFLX   404.12 (+0.25%)

Stryker (SYK) Competitors

$279.87
+1.30 (+0.47%)
(As of 11:33 AM ET)
Compare
Today's Range
$278.16
$280.11
50-Day Range
$271.49
$303.54
52-Week Range
$188.84
$306.56
Volume
348,314 shs
Average Volume
1.31 million shs
Market Capitalization
$106.02 billion
P/E Ratio
40.74
Dividend Yield
1.07%
Price Target
$302.00

SYK vs. BSX, BDX, DXCM, RMD, ELV, ISRG, MDT, GILD, AMGN, and VRTX

Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Boston Scientific (BSX), Becton, Dickinson and (BDX), DexCom (DXCM), ResMed (RMD), Elevance Health (ELV), Intuitive Surgical (ISRG), Medtronic (MDT), Gilead Sciences (GILD), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.

Stryker vs.

Stryker (NYSE:SYK) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.

Stryker has a net margin of 13.86% compared to Boston Scientific's net margin of 6.91%. Stryker's return on equity of 22.17% beat Boston Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Stryker 13.86% 22.17% 9.99%
Boston Scientific 6.91% 14.57% 7.94%

77.1% of Stryker shares are owned by institutional investors. Comparatively, 90.2% of Boston Scientific shares are owned by institutional investors. 5.9% of Stryker shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Boston Scientific had 3 more articles in the media than Stryker. MarketBeat recorded 16 mentions for Boston Scientific and 13 mentions for Stryker. Boston Scientific's average media sentiment score of 0.60 beat Stryker's score of 0.60 indicating that Boston Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stryker
5 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Boston Scientific
5 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific received 83 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.51% of users gave Boston Scientific an outperform vote while only 64.45% of users gave Stryker an outperform vote.

CompanyUnderperformOutperform
StrykerOutperform Votes
861
64.45%
Underperform Votes
475
35.55%
Boston ScientificOutperform Votes
944
69.51%
Underperform Votes
414
30.49%

Stryker presently has a consensus target price of $302.00, indicating a potential upside of 8.46%. Boston Scientific has a consensus target price of $54.00, indicating a potential upside of 4.77%. Given Stryker's higher probable upside, equities research analysts plainly believe Stryker is more favorable than Boston Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stryker
0 Sell rating(s)
8 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.60
Boston Scientific
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
3.00

Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$18.45 billion5.74$2.36 billion$6.8740.69
Boston Scientific$12.68 billion5.70$698 million$0.5987.51

Stryker has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYK vs. The Competition

MetricStrykerSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$105.91B$3.59B$4.53B$14.81B
Dividend Yield1.09%3.10%2.42%4.11%
P/E Ratio40.6922.6888.4317.22
Price / Sales5.7428.383,583.949.10
Price / Cash22.8364.5890.2823.01
Price / Book6.275.175.189.16
Net Income$2.36B$59.42M$117.76M$900.50M
7 Day Performance2.56%2.07%0.85%1.32%
1 Month Performance-4.87%0.14%2.75%1.44%
1 Year Performance19.28%-10.00%20.95%-9.56%

Stryker Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSX
Boston Scientific
2.6848 of 5 stars
$50.49
-1.1%
$53.89
+6.7%
+29.0%$70.69B$12.68B85.5845,000Analyst Report
BDX
Becton, Dickinson and
2.9214 of 5 stars
$238.31
-1.2%
$276.60
+16.1%
-1.3%$67.68B$18.87B44.7177,000
DXCM
DexCom
1.9956 of 5 stars
$113.56
-1.3%
$126.81
+11.7%
+68.5%$44.02B$2.91B162.237,600High Trading Volume
RMD
ResMed
2.643 of 5 stars
$209.98
-2.5%
$263.43
+25.5%
+7.9%$30.85B$3.58B35.778,160
ELV
Elevance Health
3.3492 of 5 stars
$441.60
-1.0%
$570.60
+29.2%
-7.0%$104.69B$156.60B17.18102,300Analyst Revision
News Coverage
ISRG
Intuitive Surgical
2.7516 of 5 stars
$307.07
+0.1%
$300.50
-2.1%
+43.5%$107.60B$6.22B83.9012,120Analyst Report
Analyst Revision
MDT
Medtronic
2.7812 of 5 stars
$82.51
+1.3%
$91.37
+10.7%
-15.4%$109.77B$31.23B29.2695,000Analyst Upgrade
GILD
Gilead Sciences
3.2254 of 5 stars
$76.33
-1.0%
$91.00
+19.2%
+17.7%$95.21B$27.28B17.2317,000Analyst Revision
AMGN
Amgen
2.6919 of 5 stars
$218.53
+0.7%
$250.94
+14.8%
-15.4%$116.77B$26.32B14.8625,200Analyst Downgrade
VRTX
Vertex Pharmaceuticals
2.0726 of 5 stars
$325.30
-1.4%
$352.59
+8.4%
+20.1%$83.78B$8.93B25.904,800Analyst Report
Analyst Revision

Related Companies and Tools

This page (NYSE:SYK) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -